Back to Search
Start Over
Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients
- Source :
- Vaccines, Volume 9, Issue 2, Vaccines, Vol 9, Iss 133, p 133 (2021)
- Publication Year :
- 2021
- Publisher :
- MDPI AG, 2021.
-
Abstract
- Introduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 peptide vaccination trial for seronegative end-stage renal disease patients waiting for kidney transplantation. Methods: The highly immunogenic nonamer peptide NLVPMVATV derived from CMV phosphoprotein 65(CMVpp65) in a water-in-oil emulsion (Montanide™) plus imiquimod (Aldara™) as an adjuvant was administered subcutaneously four times biweekly. Clinical course as well as immunological responses were monitored using IFN-γ ELISpot assays and flow cytometry for CMV-specific CD8+ T cells. Results: Peptide vaccination was well tolerated, and no drug-related serious adverse events were detected except for Grade I–II local skin reactions. Five of the 10 patients (50%) mounted any immune response (responders) and 40% of the patients presented CMV-specific CD8+ T cell responses elicited by these prophylactic vaccinations. No responders experienced CMV reactivation in the 18 months post-transplantation, while all non-responders reactivated. Conclusion: CMVpp65 peptide vaccination was safe, well tolerated, and clinically encouraging in seronegative end-stage renal disease patients waiting for kidney transplantation. Further studies with larger patient cohorts are planned.
- Subjects :
- 0301 basic medicine
T cell
Immunology
Congenital cytomegalovirus infection
lcsh:Medicine
Article
End stage renal disease
03 medical and health sciences
0302 clinical medicine
Immune system
phosphoprotein 65 (pp65) peptide vaccination
Drug Discovery
medicine
Pharmacology (medical)
030212 general & internal medicine
Kidney transplantation
Pharmacology
CMV reactivation
business.industry
ELISPOT
lcsh:R
specific T cells
renal transplantation
medicine.disease
Vaccination
030104 developmental biology
Infectious Diseases
medicine.anatomical_structure
cytomegalovirus (CMV)
business
CD8
Subjects
Details
- ISSN :
- 2076393X
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Vaccines
- Accession number :
- edsair.doi.dedup.....7b09d220ca5f5fefc096caad55665826
- Full Text :
- https://doi.org/10.3390/vaccines9020133